Targeting pd-l1 on tumor cells
AssigneeMayo Foundation for Medical Education and Research
InventorsStephen James RUSSELL, Autumn J. RUIZ, Arun AMMAYAPPAN, Kah-Whye PENG, Camilo Ayala BRETON
Life of this patent
Estimating the term…
Abstract
This document relates to materials and methods for treating cancer. For example, this document provides materials and methods for using PD-L1 targeting domains in bispecific chimeric polypeptides, chimeric transmembrane polypeptides, genetically modified viruses, nucleic acid vectors, and/or fusion-inducing cells to treat cancer.
Claims26
A method for treating cancer in a mammal, wherein said method comprises administering a bispecific chimeric polypeptide comprising a PD-L1 targeting domain and an effector domain to said mammal under conditions wherein the number of cancer cells within said mammal is reduced.
A method for treating cancer in a mammal, wherein said method comprises administering a genetically modified T cell comprising a chimeric transmembrane polypeptide under conditions wherein the number of cancer cells within said mammal is reduced, wherein said chimeric transmembrane polypeptide comprises (a) a PD-L1 targeting domain, and (b) an intracellular costimulatory signaling domain.
A method for treating cancer in a mammal, wherein said method comprises administering a fusion-inducing cell under conditions wherein said fusion-inducing cell binds to a cancer cell expressing PD-L1 to form a multicellular syncytium, wherein said multicellular syncytium is not viable, and wherein said fusion-inducing cell comprises (a) a fusogenic polypeptide, and (b) a polypeptide comprising a PD-L1 targeting domain capable of binding to said cancer cell expressing PD-L1.
22-30. (canceled)
A method for treating cancer in a mammal, wherein said method comprises administering one or more nucleic acid vectors under conditions wherein said one or more nucleic acid vectors are incorporated into a target host cell to generate a fusion-inducing cell, which fusion-inducing cell binds to a cancer cell expressing PD-L1 to form a multicellular syncytium, wherein said multicellular syncytium is not viable, and wherein said one or more nucleic acid vectors comprise (a) a nucleic acid sequence encoding a fusogenic polypeptide, and (b) a nucleic acid sequence encoding a polypeptide comprising a PD-L1 targeting domain capable of binding to said cancer cell expressing PD-L1.
32-40. (canceled)
A method for treating cancer in a mammal, wherein said method comprises administering a genetically modified virus that expresses a polypeptide comprising a PD-L1 targeting domain on its surface under conditions wherein the virus is capable of infecting a cancer cell expressing PD-L1.
42-50. (canceled)
Dependencies are inferred from the claim text.